# Contrast-Enhanced Spectral Mammography (CESM)

Source: https://onco.cc/trials/nct06311695/  
OnCo record `nct06311695` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Contrast-enhanced mammography in Breast cancer, run by European Institute of Oncology, with a status the registry has not verified recently.

## Summary

Contrast-Enhanced Spectral Mammography (CESM) is a phase 2 interventional study registered as NCT06311695 by European Institute of Oncology, with 263 participants planned, started 2020-11-16 and due to reach its primary completion in 2025-02-28. Interventions recorded: Contrast Enhanced Mammography. Conditions recorded: Breast Cancer.

Linked to the technology Contrast-enhanced mammography because the registry names it ("contrast enhanced mammography") among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06311695
- Phase: 2
- Setting: The Role of Contrast-Enhanced Spectral Mammography (CESM) in the Diagnostic Process of Breast Cancer
- Sponsor: European Institute of Oncology
- Enrolled: 263

## Sources

- ClinicalTrials.gov NCT06311695: https://clinicaltrials.gov/study/NCT06311695

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- technologies: [Contrast-enhanced mammography](https://onco.cc/technologies/contrast-enhanced-mammography/)

---
JSON: https://onco.cc/api/v1/entities/nct06311695.json